Vir Biotechnology (VIR) Current Leases (2019 - 2023)

Vir Biotechnology (VIR) reported Current Leases of $7.3 million for Q1 2023, up 75.68% sequentially from $4.1 million in Q4 2022.

Vir Biotechnology (VIR) Current Leases (2019 - 2023) Analysis & Trends

Vir Biotechnology (VIR) has 4 years of Current Leases data on file, last reported at $7.3 million in Q1 2023.

For the quarter ending Q1 2023, Current Leases changed N/A year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2023 stood at $7.3 million (changed N/A YoY), and the FY2022 full-year result was $4.1 million, changed N/A from the prior year.
Current Leases grew to $7.3 million in Q1 2023, from $4.1 million in the prior quarter.
In the past five years, Current Leases ranged from a high of $7.3 million in Q1 2023 to a low of $200000.0 in Q1 2020.
A 4-year average of $1.8 million and a median of $300000.0 in 2020 frame the typical range for Current Leases.
Peak annual rise in Current Leases reached 26.58% in 2020, while the deepest fall reached 26.58% in 2020.
Tracing VIR's Current Leases over 4 years: stood at $237000.0 in 2019, then rose by 26.58% to $300000.0 in 2020, then soared by 1279.0% to $4.1 million in 2022, then jumped by 75.68% to $7.3 million in 2023.
Business Quant data shows VIR's Current Leases at $7.3 million in Q1 2023, $4.1 million in Q4 2022, and $300000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	531,233.95
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	20.58 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	872,589.03
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	720.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	11.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	16.61 Mn
10	Vir Biotechnology	1.38 Bn	1.38 Bn	-	-

Download Data